RSS Newsfeeds

See all RSS Newsfeeds

Oct 13, 2015 7:36 AM ET

Archived: Phytesia: Specialises in the in vitro cultivation and sale of hardy orchids

iCrowdNewswire - Oct 13, 2015




Phytesia SA is a spin-off company of the University of Liege created in 2003. The company participates in development of new kinds of vegetal production thanks to the numerous possibilities offered by the techniques of in vitro culture and multiplication. It pays special attention to rare or under-used plants and seeks to develop in vitro techniques that facilitate production of a much greater number of them.After some years of work, guided by demand, the activity of the company has been exclusively concentrated on varieties of orchids that were totally ignored until now. Phytesia has selected varieties of orchids coming from cold regions and resistant to temperatures as low as -30°C, which can be cultivated in our gardens. These plants which till now were not known to the general public have become the speciality of Phytesia.Phytesia is the first company to have perfected production techniques tailored specifically to perennial orchids. As pioneers, we have come to occupy the position of worldwide leader in this domain. Today, the company has more than 60 varieties in production in the laboratory, with around twenty in large scale production with applications in the sectors of horticulture, cosmetics, the food industry and medicine.

Market – Problem

1043994 287536938057887 1122687128 n

The modern economy uses just a small proportion of the plant varieties existing on earth. This dependence on a small group of vegetal species concerns all sectors of activity that make use of plant material. Agriculture uses just thirty or so species to satisfy 95% of mankind’s nutritional needs. Decorative horticulture uses around 180 different species. Medicinal plants or plants grown for cosmetics and pharmaceuticals involve several hundred species, while scientists have identified more than 6,000 species producing interesting secondary metabolites.Many plants today remain unused because it is impossible to produce them on a large scale.

Product – Solution offered

1044799 287481498063431 835251570 n

Phytesia was born of the desire to develop in vitro techniques making it possible to produce certain rare plants in greater quantities.Everyone knows orchids; everyone has bought them at one time or another. More than 500 million plants are sold every year in Europe…Nevertheless, the varieties marketed today are varieties of tropical origin, poorly adapted to our climatic conditions. They are very often produced in greenhouses heated to 30°C that require heavy energy inputs (heating, lighting, etc.).Phytesia has selected rare varieties of orchids originating from the cold regions of the globe… Cypripedium from the Canadian Rockies, Orchis from the Alps, varieties present in the wild on the Russian steppes or in the Himalayan mountains, varieties from the Fagnes or Flanders… in short, varieties which are naturally suited to climates similar to our own.Nevertheless, many of these perennial orchids are today heading for extinction, because they are only present in a few isolated areas. Moreover, they are protected by international regulations (CITES) which forbid the harvesting of wild plants in order to protect the natural sites and safeguard the species.This is where Phytesia comes in… Our team has perfected a unique and original technique of reproducing these rare varieties. It consists in cultivating the plants in vitro to increase their number without taking plants from the wild and putting the species in danger. After more than 10 years of research, Phytesia has today nearly 60 varieties in production in vitro. Since 2013, nearly 500,000 young plants in vitro leave the laboratory every year.Greenhouses installed in the Condruz area then receive the orchids and continue their cultivation. Upon leaving the laboratory, the young plants are raised for a further three to four years before the first blooms appear and they go on sale to the general public.

1012303 286125621532352 1653978670 n

Phytesia is …

  • A unique and original product: the Phytesia laboratory is the only one in the world to have mastered in vitroproduction of a large range of perennial orchids.

  • A growing market: Since its founding, Phytesia’s sales have been growing substantially (from 35,000 plants in 2003 to around 250,000 plants in 2014).

  • A diversified market: Around forty varieties are marketed to the decorative horticulture sector (80% of the company’s present sales turnover); Phytesia also markets three varieties whose main active ingredients are used to formulate cosmetics; and one variety for therapeutic use. Future developments should also make it possible to use many varieties for the food industry.

  • Protection of biodiversity: Most perennial orchid species are now in danger of disappearing from their natural environments, and the development of a production chain has not only a business side to it but also a certain ecological interest. By marketing plants grown in the laboratory it will be possible to make them accessible while protecting their natural habitats.

  • Environmentally friendly production: Floriculture in general and the production of orchids in particular are activities that consume a lot of energy. Indeed, the majority of orchids currently being sold are of tropical origin and their production in our climate requires a lot of energy inputs (heating the greenhouses to 27°C, artificial lighting, etc.). By contrast, the range of perennial orchids developed by Phytesia needs only small energy inputs (no heating for the greenhouses, no artificial lighting).

Major contracts

Massif cypripedium fasciolatum floraison

Phytesia works together with numerous Belgian and foreign wholesalers for the distribution of perennial orchids (Flora-Holland, Floréac, IBH-Plants, Gasa, etc.). Phytesia also supplies many garden centres and mail order companies. 95% of Phytesia’s production is presently sold outside of Belgium.


Contact Information:

Pascal Lambé
Sarah Docquier

View Related News >